# Cytosorbents Corp (CTSO)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/cytosorbents-corp/ JSON: https://steadybase.io/company/cytosorbents-corp.json Checked Nov 10, 2026. Latest filing read: Aug 6, 2026.

## Company

- Legal name: Cytosorbents Corp
- Ticker: CTSO (Nasdaq)
- SEC CIK: 0001175151
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Princeton, NJ
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: cytosorbents.com
- LinkedIn: https://www.linkedin.com/company/cytosorbents
- Next earnings date: Nov 12, 2026

## Key facts

- Revenue: $37.1M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926036451/0001104659-26-036451-index.html
- Operating income: -$14.7M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926036451/0001104659-26-036451-index.html
- Net income: -$8.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926036451/0001104659-26-036451-index.html
- SG&A: $35.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926036451/0001104659-26-036451-index.html
- Employees: 129 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926036451/ctso-20251231x10k.htm
- Shares outstanding: 62,842,748 as of Jul 31, 2026 (10-Q filed Aug 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926092006/0001104659-26-092006-index.html
- Auditor: Withumsmith+Brown, Pc, East Brunswick, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926036451/ctso-20251231x10k.htm

## Business

We are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.g.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1175151/000110465926036451/ctso-20251231x10k.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $37.1M | -$14.7M | -$8.2M | $35.6M |
| Dec 31, 2024 | $35.6M | -$16.5M | -$20.7M | $33.7M |
| Dec 31, 2023 | $31.1M | -$31.9M | -$29.2M | $38.3M |
| Dec 31, 2022 | $34.7M | -$31.5M | -$32.8M | $34.3M |
| Dec 31, 2021 | $43.2M | -$22.7M | -$24.6M | $35.8M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/cytosorbents-corp.json

## Officers and directors

- Phillip P. Chan, Chief Executive Officer. LinkedIn: https://linkedin.com/in/phillip-chan-ab063. Source: Form 4 filed Sep 16, 2026, https://www.sec.gov/Archives/edgar/data/1175151/000110465926108326/0001104659-26-108326-index.htm
- Peter J. Mariani, Chief Financial Officer. LinkedIn: https://linkedin.com/in/pete-mariani-93221a15. Source: Form 4 filed Jun 16, 2026, https://www.sec.gov/Archives/edgar/data/1175151/000110465926074291/0001104659-26-074291-index.htm
- Kathleen P. Bloch, Chief Financial Officer. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/1175151/000110465926036451/ctso-20251231x10k.htm
- Kathy Bloch, former CFO. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/1175151/000110465926036451/ctso-20251231x10k.htm
- Vincent Capponi, President and COO. Source: Form 4 filed Sep 16, 2026, https://www.sec.gov/Archives/edgar/data/1175151/000110465926108247/0001104659-26-108247-index.htm
- Alan D. Sobel, Board member (per proxy). Source: DEF 14A filed Jun 25, 2026, https://www.sec.gov/Archives/edgar/data/1175151/000110465926077798/tm263197d5_def14a.htm
- Edward R. Jones, Board member (per proxy). Source: DEF 14A filed Jun 25, 2026, https://www.sec.gov/Archives/edgar/data/1175151/000110465926077798/tm263197d5_def14a.htm
- Efthymios Deliargyris, Board member (per proxy). Source: DEF 14A filed Jun 25, 2026, https://www.sec.gov/Archives/edgar/data/1175151/000110465926077798/tm263197d5_def14a.htm
- Efthymios N. Deliargyris, Named in proxy. Source: DEF 14A filed Jun 25, 2026, https://www.sec.gov/Archives/edgar/data/1175151/000110465926077798/tm263197d5_def14a.htm
- Jiny Kim, Board member (per proxy). Source: DEF 14A filed Jun 25, 2026, https://www.sec.gov/Archives/edgar/data/1175151/000110465926077798/tm263197d5_def14a.htm
- Vincent J. Capponi, Named in proxy. Source: DEF 14A filed Jun 25, 2026, https://www.sec.gov/Archives/edgar/data/1175151/000110465926077798/tm263197d5_def14a.htm

## Recent 8-K events

- Sep 23, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926109814/tm2625982d1_8k.htm
- Sep 8, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926105901/tm2624941d1_8k.htm
- Aug 14, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926097092/tm2623298d1_8k.htm
- Aug 7, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926092691/tm2622604d1_8k.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926092039/tm2622246d1_8k.htm
- Jul 6, 2026: Item 3.01, Notice of delisting or failure to meet listing standards. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926080741/tm2619724d1_8k.htm
- Jun 25, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926077584/tm2618977d1_8k.htm
- May 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1175151/000092963826001834/a8k.htm
- Apr 2, 2026: Item 3.01, Notice of delisting or failure to meet listing standards. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/tm2611004d1_8k.htm
- Mar 25, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1175151/000092963826001150/a8k.htm

## Insider trades (Form 4)

- Sep 15, 2026: Phillip P. Chan (Chief Executive Officer) bought 3,774 shares, about $22,644. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926108326/0001104659-26-108326-index.htm
- Sep 15, 2026: Alan D. Sobel (Director) bought 2,500 shares, about $15,254. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926108246/0001104659-26-108246-index.htm
- Sep 14, 2026: Vincent Capponi (President and COO) bought 2,073 shares, about $12,537. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926108247/0001104659-26-108247-index.htm
- Sep 4, 2026: Phillip P. Chan (Chief Executive Officer) bought 200,000 shares, about $70,000. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926106308/0001104659-26-106308-index.htm
- Jun 15, 2026: Peter J. Mariani (Chief Financial Officer) bought 100,000 shares, about $44,000. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926074291/0001104659-26-074291-index.htm
- Jun 15, 2026: Phillip P. Chan (Chief Executive Officer) bought 261,469 shares, about $104,898. Source: https://www.sec.gov/Archives/edgar/data/1175151/000110465926074164/0001104659-26-074164-index.htm

## Latest filings

- 8-K filed Sep 23, 2026: https://www.sec.gov/Archives/edgar/data/1175151/000110465926109814/tm2625982d1_8k.htm
- 10-K filed Mar 30, 2026: https://www.sec.gov/Archives/edgar/data/1175151/000110465926036451/ctso-20251231x10k.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/1175151/000110465926092006/ctso-20260630x10q.htm
- DEF 14A filed Jun 25, 2026: https://www.sec.gov/Archives/edgar/data/1175151/000110465926077798/tm263197d5_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/